The estimated Net Worth of Alexey Lugovskoy is at least $7.14 Million dollars as of 9 November 2020. Alexey Lugovskoy owns over 6,215 units of Morphic Inc stock worth over $4,858,284 and over the last 5 years he sold MORF stock worth over $1,276,939. In addition, he makes $1,005,180 as Chief Development Officer at Morphic Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Alexey Lugovskoy MORF stock SEC Form 4 insiders trading
Alexey has made over 8 trades of the Morphic Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 6,215 units of MORF stock worth $174,704 on 9 November 2020.
The largest trade he's ever made was selling 18,856 units of Morphic Inc stock on 1 July 2020 worth over $496,856. On average, Alexey trades about 5,333 units every 15 days since 2020. As of 9 November 2020 he still owns at least 85,248 units of Morphic Inc stock.
You can see the complete history of Alexey Lugovskoy stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Alexey Lugovskoy biography
Dr. Alexey A. Lugovskoy Ph.D. serves as Chief Development Officer of the Company. Previously, Dr. Lugovskoy served as a Vice President of Therapeutics of Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, where he worked from June 2010 to January 2016. Prior to joining Merrimack, Dr. Lugovskoy served as Associate Director of Drug Discovery at Biogen Inc., a biotechnology company, where he worked from September 2001 to June 2010. Dr. Lugovskoy has been an Assistant Editor of the journal mAbs since December 2013. Dr. Lugovskoy received an Advanced Certificate for Executives in Management, Innovation and Technology from MIT Sloan School of Management, a Ph.D. in Biophysics from Harvard University and a M.Sc. in Molecular Biophysics and a B.Sc. in Mathematics and Physics from the Moscow Institute of Physics and Technology.
What is the salary of Alexey Lugovskoy?
As the Chief Development Officer of Morphic Inc, the total compensation of Alexey Lugovskoy at Morphic Inc is $1,005,180. There are 1 executives at Morphic Inc getting paid more, with Timothy Springer having the highest compensation of $1,260,500.
How old is Alexey Lugovskoy?
Alexey Lugovskoy is 47, he's been the Chief Development Officer of Morphic Inc since 2016. There are 14 older and 5 younger executives at Morphic Inc. The oldest executive at Morphic Holding Inc is Dr. Timothy A. Springer Ph.D., 73, who is the Founder, Independent Director & Member of Scientific Advisory Board.
What's Alexey Lugovskoy's mailing address?
Alexey's mailing address filed with the SEC is C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE, A2, WALTHAM, MA, 02451.
Insiders trading at Morphic Inc
Over the last 5 years, insiders at Morphic Inc have traded over $69,316,197 worth of Morphic Inc stock and bought 3,360,997 units worth $101,882,696 . The most active insiders traders include Plc Gsk, Holdings A/S Novo, and Timothy A Springer. On average, Morphic Inc executives and independent directors trade stock every 13 days with the average trade being worth of $2,254,353. The most recent stock trade was executed by Bruce Rogers on 8 July 2024, trading 20,000 units of MORF stock currently worth $86,400.
What does Morphic Inc do?
oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. morphic tx is joining a three decade quest led by our scientific founder, tim springer, who initially discovered the integrin receptor family in the 1980s. this receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, crohn's disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention. despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs...until now.
What does Morphic Inc's logo look like?
Complete history of Alexey Lugovskoy stock trades at Morphic Inc
Morphic Inc executives and stock owners
Morphic Inc executives and other stock owners filed with the SEC include:
-
Timothy Springer,
Founder, Independent Director -
Alexey Lugovskoy,
Chief Development Officer -
Dr. Praveen P. Tipirneni M.D.,
CEO, Pres & Director -
William DeVaul,
General Counsel, Secretary -
Praveen Tipirneni,
President, Chief Executive Officer, Director -
Dr. Marc Schegerin M.B.A., M.D.,
CFO & COO -
Bruce Rogers,
Chief Scientific Officer -
Vikas Goyal,
Independent Director -
Gustav Christensen,
Independent Chairman of the Board -
Joseph Slattery,
Independent Director -
Otello Stampacchia,
Independent Director -
Norbert Bischofberger,
Independent Director -
Amir Nashat,
Independent Director -
Dr. Timothy A. Springer Ph.D.,
Founder, Independent Director & Member of Scientific Advisory Board -
Nilesh Kumar,
Independent Director -
Peter Linde,
Chief Medical Officer -
Robert Farrell,
Senior Vice President - Finance, Chief Accounting Officer -
Marc Schegerin,
Chief Financial Officer, Chief Operating Officer -
Adrian S. Ray Ph.D.,
Sr. VP and Head of Biology & Translation -
Blaise Lippa,
Sr. VP of Molecular Discovery -
William D. DeVaul Esq.,
Gen. Counsel & Sec. -
Dr. Bruce N. Rogers,
Chief Scientific Officer -
Robert E. Farrell Jr., CPA, CPA,
Sr. VP of Fin./Operations & Chief Accounting Officer -
Susannah Gray,
-
Nisha Nanda,
-
Martin Edwards,
-
Holdings A/S Novo,
10% owner -
Plc Gsk,
Director -
Otello Stampacchia,
Director -
Fund V, L.P.Omega Fund V Gp...,
-
Simon Peter Cooper,
CMO